• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嵌合抗原受体 T 细胞携带疱疹病毒进入介质共刺激信号域,表现出抗衰竭特性。

Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties.

机构信息

Department of Microbiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan.

出版信息

Int J Mol Sci. 2024 Aug 8;25(16):8662. doi: 10.3390/ijms25168662.

DOI:10.3390/ijms25168662
PMID:39201348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11354286/
Abstract

Improving chimeric antigen receptor (CAR)-T cell therapeutic outcomes and expanding its applicability to solid tumors requires further refinement of CAR-T cells. We previously reported that CAR-T cells bearing a herpes virus entry mediator (HVEM)-derived co-stimulatory signal domain (CSSD) (HVEM-CAR-T cells) exhibit superior functions and characteristics. Here, we conducted comparative analyses to evaluate the impact of different CSSDs on CAR-T cell exhaustion. The results indicated that HVEM-CAR-T cells had significantly lower frequencies of exhausted cells and exhibited the highest proliferation rates upon antigenic stimulation. Furthermore, proliferation inhibition by programmed cell death ligand 1 was stronger in CAR-T cells bearing CD28-derived CSSD (CD28-CAR-T cells) whereas it was weaker in HVEM-CAR-T. Additionally, HVEM-CAR-T cells maintained a low exhaustion level even after antigen-dependent proliferation and exhibited potent killing activities, suggesting that HVEM-CAR-T cells might be less prone to early exhaustion. Analysis of CAR localization on the cell surface revealed that CAR formed clusters in CD28-CAR-T cells whereas uniformly distributed in HVEM-CAR-T cells. Analysis of CD3ζ phosphorylation indicated that CAR-dependent tonic signals were strongly sustained in CD28-CAR-T cells whereas they were significantly weaker in HVEM-CAR-T cells. Collectively, these results suggest that the HVEM-derived CSSD is useful for generating CAR-T cells with exhaustion-resistant properties, which could be effective against solid tumors.

摘要

为了提高嵌合抗原受体(CAR)-T 细胞治疗效果,并将其应用扩展到实体瘤,需要对 CAR-T 细胞进行进一步的改进。我们之前报道过,携带疱疹病毒进入介质(HVEM)衍生的共刺激信号结构域(CSSD)的 CAR-T 细胞(HVEM-CAR-T 细胞)具有更优越的功能和特性。在这里,我们进行了比较分析,以评估不同 CSSD 对 CAR-T 细胞耗竭的影响。结果表明,HVEM-CAR-T 细胞中耗尽细胞的频率明显较低,在抗原刺激下表现出最高的增殖率。此外,在携带 CD28 衍生 CSSD 的 CAR-T 细胞(CD28-CAR-T 细胞)中,程序性细胞死亡配体 1 的增殖抑制作用更强,而在 HVEM-CAR-T 细胞中则较弱。此外,HVEM-CAR-T 细胞即使在抗原依赖性增殖后仍保持低耗竭水平,并表现出强大的杀伤活性,表明 HVEM-CAR-T 细胞可能不易早期耗竭。CAR 在细胞表面的定位分析表明,CAR 在 CD28-CAR-T 细胞中形成簇,而在 HVEM-CAR-T 细胞中均匀分布。CD3ζ 磷酸化分析表明,CD28-CAR-T 细胞中强烈持续地维持着 CAR 依赖性的紧张信号,而在 HVEM-CAR-T 细胞中则显著较弱。总之,这些结果表明,HVEM 衍生的 CSSD 可用于产生具有抗耗竭特性的 CAR-T 细胞,这可能对实体瘤有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/181913c18224/ijms-25-08662-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/aec08318a56d/ijms-25-08662-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/bd89a55453ae/ijms-25-08662-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/47038a72cdd8/ijms-25-08662-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/9fa575ea9ddf/ijms-25-08662-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/7d2998996771/ijms-25-08662-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/181913c18224/ijms-25-08662-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/aec08318a56d/ijms-25-08662-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/bd89a55453ae/ijms-25-08662-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/47038a72cdd8/ijms-25-08662-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/9fa575ea9ddf/ijms-25-08662-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/7d2998996771/ijms-25-08662-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6a/11354286/181913c18224/ijms-25-08662-g006.jpg

相似文献

1
Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties.嵌合抗原受体 T 细胞携带疱疹病毒进入介质共刺激信号域,表现出抗衰竭特性。
Int J Mol Sci. 2024 Aug 8;25(16):8662. doi: 10.3390/ijms25168662.
2
Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-stimulatory Signal Domain Exhibits High Functional Potency.携带疱疹病毒进入介质共刺激信号域的嵌合抗原受体T细胞具有高效能。
Mol Ther Oncolytics. 2019 Mar 23;14:27-37. doi: 10.1016/j.omto.2019.03.002. eCollection 2019 Sep 27.
3
Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.单纯疱疹病毒进入介质共刺激信号通过代谢重编程增强 CAR T 细胞对实体瘤的疗效。
Cancer Immunol Res. 2023 Apr 3;11(4):515-529. doi: 10.1158/2326-6066.CIR-22-0531.
4
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.4-1BB 共刺激和优化的 CD28 共刺激增强了人单特异性和双特异性第三代 CAR T 细胞的功能。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003354.
5
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.嵌合抗原受体 T 细胞共转导 CD28 和 4-1BB 基因在 B 细胞白血病患者体内的扩增与抗肿瘤活性。
Mol Ther. 2018 Apr 4;26(4):976-985. doi: 10.1016/j.ymthe.2018.01.022. Epub 2018 Feb 2.
6
The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.BTLA-HVEM 轴限制了癌症中 CAR T 细胞的疗效。
Nat Immunol. 2024 Jun;25(6):1020-1032. doi: 10.1038/s41590-024-01847-4. Epub 2024 Jun 3.
7
Concanavalin A-mediated T cell proliferation is regulated by herpes virus entry mediator costimulatory molecule.伴刀豆球蛋白A介导的T细胞增殖受疱疹病毒进入介质共刺激分子调控。
In Vitro Cell Dev Biol Anim. 2014 Apr;50(4):313-20. doi: 10.1007/s11626-013-9705-2. Epub 2013 Oct 26.
8
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.表达 PD-1/CD28 嵌合开关受体的 CD19 特异性 CAR T 细胞在 PD-L1 阳性 B 细胞淋巴瘤患者中有效。
Clin Cancer Res. 2021 Jan 15;27(2):473-484. doi: 10.1158/1078-0432.CCR-20-1457. Epub 2020 Oct 7.
9
Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals.第二代嵌合抗原受体信号转导结构域调控 CAR 信号输入效率
Int J Mol Sci. 2021 Mar 1;22(5):2476. doi: 10.3390/ijms22052476.
10
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.一种新型嵌合抗原受体,包含 JAK-STAT 信号域,介导优越的抗肿瘤效应。
Nat Med. 2018 Mar;24(3):352-359. doi: 10.1038/nm.4478. Epub 2018 Feb 5.

本文引用的文献

1
State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?嵌合抗原受体 T 细胞疗法治疗实体瘤的最新进展:未来是否更加美好?
Cells. 2024 Apr 23;13(9):725. doi: 10.3390/cells13090725.
2
T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.嵌合抗原受体 T 细胞(CAR-T)疗法中的 T 细胞耗竭及其克服策略。
Immunology. 2023 Aug;169(4):400-411. doi: 10.1111/imm.13642. Epub 2023 Mar 20.
3
Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.
单纯疱疹病毒进入介质共刺激信号通过代谢重编程增强 CAR T 细胞对实体瘤的疗效。
Cancer Immunol Res. 2023 Apr 3;11(4):515-529. doi: 10.1158/2326-6066.CIR-22-0531.
4
CAR-T cell potency: from structural elements to vector backbone components.嵌合抗原受体T细胞效力:从结构元件到载体骨架组件
Biomark Res. 2022 Sep 19;10(1):70. doi: 10.1186/s40364-022-00417-w.
5
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.改善 CAR-T 免疫疗法:克服 T 细胞耗竭的挑战。
EBioMedicine. 2022 Mar;77:103941. doi: 10.1016/j.ebiom.2022.103941. Epub 2022 Mar 15.
6
The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity.在嵌合抗原受体T细胞(CAR-T细胞)中实施肿瘤坏死因子受体超家族(TNFRSF)共刺激结构域以实现最佳功能活性
Cancers (Basel). 2022 Jan 8;14(2):299. doi: 10.3390/cancers14020299.
7
Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy.抗肿瘤 T 细胞中 PRDM1 的基因缺失增强了过继免疫疗法的治疗效果。
Blood. 2022 Apr 7;139(14):2156-2172. doi: 10.1182/blood.2021012714.
8
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling.框架区修饰消除嵌合抗原受体 T 细胞持续激活信号
Cancer Immunol Res. 2021 Apr;9(4):441-453. doi: 10.1158/2326-6066.CIR-20-0451. Epub 2021 Feb 5.
9
Engineering strategies to overcome the current roadblocks in CAR T cell therapy.克服 CAR T 细胞疗法当前障碍的工程策略。
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167. doi: 10.1038/s41571-019-0297-y. Epub 2019 Dec 17.
10
c-Jun overexpression in CAR T cells induces exhaustion resistance.CAR T 细胞中 c-Jun 的过表达诱导衰竭抵抗。
Nature. 2019 Dec;576(7786):293-300. doi: 10.1038/s41586-019-1805-z. Epub 2019 Dec 4.